TScan Therapeutics (TCRX) said Thursday that it signed a securities purchase agreement with Lynx1 Capital Management and an investment fund advised by Lynx1 for the sale of about $30 million of pre-funded warrants.
Under the terms of the deal, the warrants allow Lynx1 to purchase up to 7.5 million shares of TScan's voting common stock for $4 per pre-funded warrant, representing a premium of 37% to the last closing price of TScan's common stock and a 34% premium over the 10-day volume weighted average closing price, according to TScan.
The financing is expected to close Friday, the company added.
Shares of TScan jumped more than 20% in recent premarket activity Thursday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。